A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.

Trial Details

NCT ID
NCT06876662
Phase
PHASE4
Sponsor
Eli Lilly and Company
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Pirtobrutinib
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366
  • Sarasota, Florida, United States|27.33643,-82.53065
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Are currently enrolled and active in the originator study, LOXO-BTK-18001. A participant is considered active in the study if they are:
  • receiving study intervention
  • in the short-term follow-up period, or
  • in the long-term follow-up period

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →